Figure 5i, j shows that the expression levels of SMYD2 and SMAD3 decreased at the transcriptional and translational levels, implying that downregulation of SMAD3 by SMYD2 affects lung cancer metastasis in vivo. This evidence concerns the gene SMAD3 and lung carcinoma.